Abstract：Objective To investigate the effect of Bifidobacterium Quadruple Live Tablets combined with Mesalazine on serum C-reactive protein (CRP) levels and adverse reactions in patients with ulcerative colitis (UC).Methods Eightysix patients with UC admitted to our hospital from January 2016 to September 2019 were enrolled in the study.They were divided into control group and observation group according to the random number table method, 43 cases in each group.The control group was treated with Mesalazine Enteric-Coated Tablets orally；the observation group was treated with Mesalazine Enteric-Coated Tablets and Bifidobacterium Quadruple Live Tablets；the patients in both groups were given continuous medication for 2 months.The treatment efficiency, c-reactive protein (CRP), interleukin-4 (IL-4), interleukin-8 (IL-8) index, disease activity index (Mayo) score, and adverse reactions were compared between the two groups.Results After 2 months of treatment, the effective rate of treatment in the observation group (95.35%) was higher than that in the control group (79.07%), and IL-4 (1.38±0.28) ng/ml was higher than that the control group for(0.94±0.31) ng/ml, CRP (7.85±2.74) mg/L, IL-8 index (17.64±4.59) μg/L, were lower than those of the control group(13.68±3.62) mg/L, (25.54±5.87) μg/L, Mayo score (3.42±0.44), and adverse reaction rate (6.98%) were lower than that in the control group for (5.84±0.38), the tatal of incidence of aduorse reactions (6.98%) was lower than that of the control group (25.58%), the differences were statistically significant (P＜0.05).Conclusion Bifidobacterium Quadruple Live Tablets combined with Mesalazine can effectively treat UC.It has synergistic therapeutic effect, can improve the treatment efficiency, regulate the levels of CRP, IL-4 and IL-8, and improve the immune function of the body, reducing the occurrence of adverse reactions, high safety, and huge prospects for clinical application, it is worth promoting.
京公网安备 11010502046607号